The logo of Danish pharmaceutical company Novo Nordisk is pictured at their headquarters in Bagsvaerd, Denmark, on Feb. 1, 2017. Liselotte Sabroe/Scanpix Denmark/AFP via Getty ImagesStock prices for Denmark-based Novo Nordisk dropped by more than 15 percent on Feb. 23 after the global healthcare firm announced disappointing results from a clinical trial of CagriSema.Known for its Ozempic injectable medication for treating diabetes and obesity, Novo Nordisk’s newest pharmaceutical just completed its phase 3 trial, called REDEFINE 4, an 84-week trial test of CagriSema, a combination of cagrilintide 2.4 mg and semaglutide 2.4 mg injectable.
-8.1
C
Ottawa
Monday, February 23, 2026
The Alliance Press is the world leader in online chained news and information and seeks to inform, engage and empower the world. We expose the information that wasn't known before or current events broadcast over the radio, television, online or in print media. Our content is now available through your mobile phone. No matter where your on-the-go lifestyle takes you, TAP brings the news directly to you.
More from CN
Contact
© The Alliance Media Group design by CODEUS